Previous 10 | Next 10 |
Summary During the third quarter of 2022, the Miller Opportunity Equity strategy generated a total return of -4.62% net of fees. Using a three-factor performance attribution model, allocation, and selection effects contributed to the strategy’s outperformance which was part...
The Best Penny Stocks To Buy Are you like most traders right now, looking for the best penny stocks to buy? You’re not alone, but the task isn’t as easy as finding a cheap stock, buying it, and getting rich with penny stocks . There’s a plan to follow in order t...
Precigen ( NASDAQ: PGEN ) on Wednesday named Rutul Shah as the Company's Chief Operating Officer, effective October 1. Shah has been working with the company since 2014 and has served as Head of Operations and Portfolio as his most recent role. Shah will have resp...
Precigen Names Rutul R. Shah Chief Operating Officer PR Newswire GERMANTOWN, Md. , Sept. 21 , 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to impr...
Precigen to Participate in the 2022 Wells Fargo Healthcare Conference PR Newswire GERMANTOWN, Md. , Sept. 1, 2022 /PRNewswire/ -- Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell th...
Today, we circle back on Precigen, a biotech firm that was once part of Intrexon. Precigen is advancing several drug candidates in its pipeline and recently agreed to a divesture than significantly bolstered its financial situation. An investment analysis of Precigen follows in th...
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics PR Newswire – Proceeds include $170 million in upfront cash and up to $10 million earn-out over two years – GERMANTOWN, Md. , Aug. 22, 2022 /PRNewswire/ ...
Precigen ( NASDAQ: PGEN ) stock added 12.9% to $2.32 in Tuesday afternoon trading, after the clinical-stage biopharmaceutical company reported a Q2 bottom line beat. Germantown, Md.-based PGEN develops gene and cell therapies. Its pipeline consists of the AG019 product w...
Precigen, Inc. (PGEN) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Steven Harasym - Vice President and Head of Investor Relations Helen Sabzevari - President and Chief Executive Officer Harry Thomasian - Chief Financial Office...
The following slide deck was published by Precigen, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Precigen, Inc. 2022 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...